Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 7823

BillFederalHouseIn Committee
To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes.
About This Bill
Committee
Latest Action · March 29, 2024
Referred to the Subcommittee on Health.
Congress
118th (2023–2025)
Introduced
March 26, 2024
Cosponsors (11)
0D 11R
View PDF ↗

Summary

Highlight any text to annotate
The Second Chance for Moms Act would require mifepristone, a medication used in medication abortion, to carry a warning label stating that the drug's effects can allegedly be counteracted by natural progesterone and directing women to call a federal hotline for more information. The bill would also establish a federally-funded, toll-free hotline operating 24 hours a day, seven days a week, to provide information and support to women seeking to reverse mifepristone's effects. The warning label requirement would take effect six months after the bill becomes law. This legislation would affect women who take mifepristone and the federal healthcare system, though the bill does not specify funding amounts for the hotline. The bill was introduced in March 2024 and referred to the House Committee on Energy and Commerce.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.